NR 546 PSYCHOPHARMACOLOGY FOR THE
PSYCHIATRIC-MENTAL HEALTH NURSE
PRACTITIONER EXAM QUESTIONS AND ANSWERS |
VERIFIED AND WELL DETAILED ANSWERS | PLUS
RATIONALES | DOWNLOAD AND PASS | LATEST
EXAM UPDATE 2026/2027
Core Domains:
Neuropharmacology Foundations and Neurotransmitter Systems (Receptors, Pathways, Signal
Transduction)
Pharmacokinetics and Pharmacodynamics (ADME, CYP450, Half-Life, Steady State)
Antidepressant and Anxiolytic Pharmacotherapy (SSRIs, SNRIs, MAOIs, Benzodiazepines)
Antipsychotic and Mood Stabilizer Pharmacotherapy (Typical/Atypical, Lithium, Valproate,
Lamotrigine)
Stimulant, Cognitive Enhancer, and Substance Use Pharmacotherapy (ADHD, Nicotine,
Alcohol)
Special Populations and Clinical Application in Psychopharmacology (Pregnancy, Geriatrics,
Comorbidities)
Pharmacogenomics and Personalized Medicine (CYP450, HLA Typing)
Ethical and Legal Issues in Psychiatric Prescribing
Psychotropic Drug Interactions and Adverse Effects
This comprehensive examination guide is designed to prepare students for the NR546
Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner course at
Chamberlain University. The examination evaluates advanced psychopharmacology knowledge
essential for PMHNP practice, including neuropharmacology foundations, pharmacokinetic
principles, and the mechanisms of action of psychotropic medications across all major drug
classes. Questions are structured to assess clinical reasoning, medication selection, and the
application of psychopharmacological concepts to real-world patient scenarios. Each item
includes a verified correct answer accompanied by a detailed rationale to reinforce learning and
support exam preparation for the 2026/2027 academic year.
SECTION ONE: QUESTIONS 1 – 100
Question 1
,A 34-year-old woman with major depressive disorder has been prescribed an SSRI that
selectively blocks the serotonin transporter. The nurse practitioner understands that the
therapeutic effect of SSRIs is mediated through which downstream cellular mechanism?
A. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased serotonergic
neurotransmission
B. Direct agonist at postsynaptic 5-HT2A receptors in the prefrontal cortex
C. Inhibition of monoamine oxidase type A in the presynaptic terminal
D. Blockade of serotonin reuptake at the postsynaptic membrane
A. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased serotonergic
neurotransmission
RATIONALE: SSRIs block the serotonin transporter (SERT), increasing synaptic serotonin.
Initially, presynaptic 5-HT1A autoreceptors limit serotonin release, but with chronic treatment
(2-4 weeks), these autoreceptors desensitize, allowing full enhancement of serotonergic
neurotransmission. This delayed desensitization explains the therapeutic lag of SSRIs .
Question 2
A 42-year-old man with schizophrenia has elevated prolactin levels causing gynecomastia and
galactorrhea. His current antipsychotic medication is known to block dopamine D2 receptors in
the tuberoinfundibular pathway. Which mechanism explains the hyperprolactinemia?
A. Histamine H1 receptor antagonism increases prolactin synthesis
B. Dopamine normally inhibits prolactin release; D2 blockade removes this inhibitory tone
C. Dopamine stimulates prolactin release; D2 blockade enhances pituitary function
D. Serotonin reuptake inhibition increases prolactin-releasing hormone
B. Dopamine normally inhibits prolactin release; D2 blockade removes this inhibitory tone
RATIONALE: In the tuberoinfundibular pathway, dopamine acts as a prolactin-inhibiting
factor (PIF) by binding to D2 receptors on lactotroph cells in the anterior pituitary. When
antipsychotics block these D2 receptors, the inhibitory tone on prolactin secretion is removed,
leading to hyperprolactinemia and its clinical consequences .
Question 3
A psychiatric nurse practitioner is teaching a patient about the blood-brain barrier and
psychotropic drug delivery. Lipophilicity of a medication most directly determines which
pharmacokinetic property?
A. Affinity for receptor binding sites on postsynaptic membranes
B. Duration of action in the synaptic cleft before reuptake
,C. Ability to cross the blood-brain barrier and reach central nervous system targets
D. Rate of hepatic metabolism by cytochrome P450 enzymes
C. Ability to cross the blood-brain barrier and reach central nervous system targets
RATIONALE: The blood-brain barrier consists of endothelial tight junctions that restrict
paracellular transport. Lipophilic (fat-soluble) drugs can passively diffuse through the
endothelial cell membranes of the BBB, while hydrophilic drugs cannot. Most antipsychotic
medications are designed to be lipophilic to ensure adequate CNS penetration .
Question 4
A 28-year-old patient with bipolar disorder is prescribed a medication that blocks voltage-gated
sodium channels and inhibits glutamate release. This mechanism of action is most consistent
with which medication?
A. Carbamazepine
B. Lithium carbonate
C. Valproic acid
D. Lamotrigine
D. Lamotrigine
RATIONALE: Lamotrigine blocks voltage-gated sodium channels, stabilizing neuronal
membranes and inhibiting glutamate release. This mechanism contributes to its mood-stabilizing
effects, particularly in bipolar depression .
Question 5
A 34-year-old woman with treatment-resistant depression is being evaluated for
pharmacogenomic testing. The PMHNP explains that the CYP2D6 enzyme is considered a poor
metabolizer phenotype. This phenotype is most likely to result in which clinical consequence
when prescribing a substrate of CYP2D6?
A. Rapid drug clearance requiring extended-release formulations
B. Enhanced first-pass metabolism reducing oral bioavailability
C. Subtherapeutic drug levels requiring dose escalation
D. Elevated drug levels increasing the risk of adverse effects
D. Elevated drug levels increasing the risk of adverse effects
RATIONALE: CYP2D6 is a major hepatic enzyme responsible for metabolizing many
psychotropic drugs, including most SSRIs and TCAs. Poor metabolizers have reduced enzyme
activity, leading to elevated drug levels and increased risk of adverse effects .
, Question 6
A 42-year-old man begins taking fluoxetine 20 mg daily for major depressive disorder. He is also
prescribed tramadol for chronic back pain by his primary care provider. The PMHNP should be
most concerned about which interaction?
A. Decreased fluoxetine levels from CYP2D6 inhibition by tramadol
B. Reduced analgesic efficacy of tramadol due to CYP3A4 induction
C. Serotonin syndrome risk due to combined serotonergic effects
D. Increased seizure threshold from combined GABAergic activity
C. Serotonin syndrome risk due to combined serotonergic effects
RATIONALE: Fluoxetine (an SSRI) and tramadol (a weak opioid with serotonin and
norepinephrine reuptake inhibition) both increase serotonergic tone, creating a significant risk for
serotonin syndrome. Tramadol is not a CYP3A4 inducer, and the combination does not increase
the seizure threshold; tramadol actually lowers it .
Question 7
A 28-year-old patient with schizophrenia has been stable on clozapine for 2 years. Routine
monitoring reveals a white blood cell count of 2,800/microL and an absolute neutrophil count of
1,100/microL. The PMHNP understands that clozapine-induced agranulocytosis is mediated by
which mechanism?
A. CYP1A2 metabolic accumulation leading to cellular toxicity
B. Hapten formation triggering complement-mediated neutrophil lysis
C. Direct dose-dependent bone marrow suppression
D. Immune-mediated destruction of neutrophil precursors
D. Immune-mediated destruction of neutrophil precursors
RATIONALE: Clozapine-induced agranulocytosis is an idiosyncratic, immune-mediated
reaction involving antibodies against neutrophil precursors, not a dose-dependent bone marrow
suppressive effect. CYP1A2 metabolism affects clozapine levels but does not directly cause
agranulocytosis .
Question 8
A PMHNP is explaining the dopamine hypothesis of schizophrenia to a nursing student. The
student asks which dopaminergic pathway is most directly associated with the positive symptoms
of schizophrenia, such as delusions and hallucinations.
PSYCHIATRIC-MENTAL HEALTH NURSE
PRACTITIONER EXAM QUESTIONS AND ANSWERS |
VERIFIED AND WELL DETAILED ANSWERS | PLUS
RATIONALES | DOWNLOAD AND PASS | LATEST
EXAM UPDATE 2026/2027
Core Domains:
Neuropharmacology Foundations and Neurotransmitter Systems (Receptors, Pathways, Signal
Transduction)
Pharmacokinetics and Pharmacodynamics (ADME, CYP450, Half-Life, Steady State)
Antidepressant and Anxiolytic Pharmacotherapy (SSRIs, SNRIs, MAOIs, Benzodiazepines)
Antipsychotic and Mood Stabilizer Pharmacotherapy (Typical/Atypical, Lithium, Valproate,
Lamotrigine)
Stimulant, Cognitive Enhancer, and Substance Use Pharmacotherapy (ADHD, Nicotine,
Alcohol)
Special Populations and Clinical Application in Psychopharmacology (Pregnancy, Geriatrics,
Comorbidities)
Pharmacogenomics and Personalized Medicine (CYP450, HLA Typing)
Ethical and Legal Issues in Psychiatric Prescribing
Psychotropic Drug Interactions and Adverse Effects
This comprehensive examination guide is designed to prepare students for the NR546
Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner course at
Chamberlain University. The examination evaluates advanced psychopharmacology knowledge
essential for PMHNP practice, including neuropharmacology foundations, pharmacokinetic
principles, and the mechanisms of action of psychotropic medications across all major drug
classes. Questions are structured to assess clinical reasoning, medication selection, and the
application of psychopharmacological concepts to real-world patient scenarios. Each item
includes a verified correct answer accompanied by a detailed rationale to reinforce learning and
support exam preparation for the 2026/2027 academic year.
SECTION ONE: QUESTIONS 1 – 100
Question 1
,A 34-year-old woman with major depressive disorder has been prescribed an SSRI that
selectively blocks the serotonin transporter. The nurse practitioner understands that the
therapeutic effect of SSRIs is mediated through which downstream cellular mechanism?
A. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased serotonergic
neurotransmission
B. Direct agonist at postsynaptic 5-HT2A receptors in the prefrontal cortex
C. Inhibition of monoamine oxidase type A in the presynaptic terminal
D. Blockade of serotonin reuptake at the postsynaptic membrane
A. Desensitization of presynaptic 5-HT1A autoreceptors leading to increased serotonergic
neurotransmission
RATIONALE: SSRIs block the serotonin transporter (SERT), increasing synaptic serotonin.
Initially, presynaptic 5-HT1A autoreceptors limit serotonin release, but with chronic treatment
(2-4 weeks), these autoreceptors desensitize, allowing full enhancement of serotonergic
neurotransmission. This delayed desensitization explains the therapeutic lag of SSRIs .
Question 2
A 42-year-old man with schizophrenia has elevated prolactin levels causing gynecomastia and
galactorrhea. His current antipsychotic medication is known to block dopamine D2 receptors in
the tuberoinfundibular pathway. Which mechanism explains the hyperprolactinemia?
A. Histamine H1 receptor antagonism increases prolactin synthesis
B. Dopamine normally inhibits prolactin release; D2 blockade removes this inhibitory tone
C. Dopamine stimulates prolactin release; D2 blockade enhances pituitary function
D. Serotonin reuptake inhibition increases prolactin-releasing hormone
B. Dopamine normally inhibits prolactin release; D2 blockade removes this inhibitory tone
RATIONALE: In the tuberoinfundibular pathway, dopamine acts as a prolactin-inhibiting
factor (PIF) by binding to D2 receptors on lactotroph cells in the anterior pituitary. When
antipsychotics block these D2 receptors, the inhibitory tone on prolactin secretion is removed,
leading to hyperprolactinemia and its clinical consequences .
Question 3
A psychiatric nurse practitioner is teaching a patient about the blood-brain barrier and
psychotropic drug delivery. Lipophilicity of a medication most directly determines which
pharmacokinetic property?
A. Affinity for receptor binding sites on postsynaptic membranes
B. Duration of action in the synaptic cleft before reuptake
,C. Ability to cross the blood-brain barrier and reach central nervous system targets
D. Rate of hepatic metabolism by cytochrome P450 enzymes
C. Ability to cross the blood-brain barrier and reach central nervous system targets
RATIONALE: The blood-brain barrier consists of endothelial tight junctions that restrict
paracellular transport. Lipophilic (fat-soluble) drugs can passively diffuse through the
endothelial cell membranes of the BBB, while hydrophilic drugs cannot. Most antipsychotic
medications are designed to be lipophilic to ensure adequate CNS penetration .
Question 4
A 28-year-old patient with bipolar disorder is prescribed a medication that blocks voltage-gated
sodium channels and inhibits glutamate release. This mechanism of action is most consistent
with which medication?
A. Carbamazepine
B. Lithium carbonate
C. Valproic acid
D. Lamotrigine
D. Lamotrigine
RATIONALE: Lamotrigine blocks voltage-gated sodium channels, stabilizing neuronal
membranes and inhibiting glutamate release. This mechanism contributes to its mood-stabilizing
effects, particularly in bipolar depression .
Question 5
A 34-year-old woman with treatment-resistant depression is being evaluated for
pharmacogenomic testing. The PMHNP explains that the CYP2D6 enzyme is considered a poor
metabolizer phenotype. This phenotype is most likely to result in which clinical consequence
when prescribing a substrate of CYP2D6?
A. Rapid drug clearance requiring extended-release formulations
B. Enhanced first-pass metabolism reducing oral bioavailability
C. Subtherapeutic drug levels requiring dose escalation
D. Elevated drug levels increasing the risk of adverse effects
D. Elevated drug levels increasing the risk of adverse effects
RATIONALE: CYP2D6 is a major hepatic enzyme responsible for metabolizing many
psychotropic drugs, including most SSRIs and TCAs. Poor metabolizers have reduced enzyme
activity, leading to elevated drug levels and increased risk of adverse effects .
, Question 6
A 42-year-old man begins taking fluoxetine 20 mg daily for major depressive disorder. He is also
prescribed tramadol for chronic back pain by his primary care provider. The PMHNP should be
most concerned about which interaction?
A. Decreased fluoxetine levels from CYP2D6 inhibition by tramadol
B. Reduced analgesic efficacy of tramadol due to CYP3A4 induction
C. Serotonin syndrome risk due to combined serotonergic effects
D. Increased seizure threshold from combined GABAergic activity
C. Serotonin syndrome risk due to combined serotonergic effects
RATIONALE: Fluoxetine (an SSRI) and tramadol (a weak opioid with serotonin and
norepinephrine reuptake inhibition) both increase serotonergic tone, creating a significant risk for
serotonin syndrome. Tramadol is not a CYP3A4 inducer, and the combination does not increase
the seizure threshold; tramadol actually lowers it .
Question 7
A 28-year-old patient with schizophrenia has been stable on clozapine for 2 years. Routine
monitoring reveals a white blood cell count of 2,800/microL and an absolute neutrophil count of
1,100/microL. The PMHNP understands that clozapine-induced agranulocytosis is mediated by
which mechanism?
A. CYP1A2 metabolic accumulation leading to cellular toxicity
B. Hapten formation triggering complement-mediated neutrophil lysis
C. Direct dose-dependent bone marrow suppression
D. Immune-mediated destruction of neutrophil precursors
D. Immune-mediated destruction of neutrophil precursors
RATIONALE: Clozapine-induced agranulocytosis is an idiosyncratic, immune-mediated
reaction involving antibodies against neutrophil precursors, not a dose-dependent bone marrow
suppressive effect. CYP1A2 metabolism affects clozapine levels but does not directly cause
agranulocytosis .
Question 8
A PMHNP is explaining the dopamine hypothesis of schizophrenia to a nursing student. The
student asks which dopaminergic pathway is most directly associated with the positive symptoms
of schizophrenia, such as delusions and hallucinations.
